Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer

Haiderali, Amin; Rhodes, Whitney; Gautam, Santosh; Huang, Min; Sieluk, Jan; Skinner, Karen E; Schwartzberg, Lee S.

doi:10.2217/fon-2021-0530

Cited by 4 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean age of patients in our study was 52.2 years, and the literature data were found to be consistent. [12][13][14][15][16][17][18] Although a significant relationship was observed between age and OS in our study, no significant relationship was found in the study by Costa et al 18 The histological grade is among the best established prognostic factors for breast cancer, and the majority of patients with TNBC have a high tumor grade. 5 Consistent with the literature, the majority of patients in our cohort also had a high tumor grade and their OS was worse, again similar to that reported in the literature.…”

Section: Discussioncontrasting

confidence: 61%

“…5 Consistent with the literature, the majority of patients in our cohort also had a high tumor grade and their OS was worse, again similar to that reported in the literature. [12][13][14][15][16][17][18] Only a few other smaller studies have reported that grade has no role in determining survival outcomes. 17,19 Certain studies have reported that tumor size and lymph node status are significantly associated with OS in patients with TNBC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience

DOĞAN¹,

Ayhan²

2022

J Oncol Sci

View full text Add to dashboard Cite

We determined the prognostic factors of patients with triple-negative breast cancer. Material and Method: Two hundred thirteen female patients with triple-negative breast cancer (TNBC) followed in the medical oncology unit of Kartal Doctor Lütfi Kırdar City Hospital between 2005 and 2020 were evaluated retrospectively. Patients' clinical and demographic features, laboratory findings, and treatments were investigated and their effect on mortality was analyzed. Results: The median age of patients was 52 years. Relapse was observed in 46 (26.6%) patients, 127 patients were followed without progression. During the follow-up period, 57 patients died and 156 patients survived. The median overall survival was 137.2 months in patients with tumor size <2 cm, 109.9 months in patients with ≥2 cm and <5 cm, and 90.5 months in patients with ≥5 cm (p=0.02). Tumor diameter, lymph node positivity, menopausal status, and whether receiving neoadjuvant chemotherapy were determined as factors affecting the overall survival. Conclusion: In accordance with the literature, patients with TNBC showed more aggressive characteristics. Our findings support that TNBC is a heterogeneous disease and highlight the need to define molecular subclasses. We believe that demographic and prognostic data studies with large patient series and determining molecular markers will guide the follow-up and treatment of patients with TNBC.

show abstract

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience

DOĞAN¹,

Ayhan²

2022

J Oncol Sci

View full text Add to dashboard Cite

show abstract

“…This is in contrast to a recent study investigating real-world treatment patterns in early-stage TNBC, which demonstrated that the majority of patients who received either neoadjuvant or adjuvant chemotherapy received an ABR. 25 In addition, the pCR rates in our study of 48.2% and 21.4% in the ASR and ABR groups respectively trend in favor of the ASR group. However, this finding was ultimately not statistically significant likely due to the small sample size of our ABR cohort.…”

Section: Discussionmentioning

confidence: 48%

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

et al. 2022

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis when compared to hormone receptor–positive breast cancers. Anthracycline-based regimens (ABRs) are mainstay for treatment of non-metastatic TNBC. However, anthracyclines are associated with an increased risk of potentially life-threatening adverse effects. We sought to evaluate outcomes in patients with early TNBC treated with ABRs versus those treated with anthracycline-sparing regimens (ASRs). Methods: All patients treated for stage I–III TNBC who had undergone curative-intent surgery at a large academic medical center between January 2013 and May 2018 were included in this retrospective study. Event-free survival (EFS) and disease-free survival (DFS) were the primary endpoints, with overall survival (OS) as a secondary endpoint and were defined as per standardized STEEP criteria. Kaplan–Meier, multivariable Cox regression, and log-rank tests were used to define key survival and treatment-related differences between subjects treated with ABRs versus ASRs. Results: One hundred thirty-two patients met inclusion criteria with a median follow-up of 55.9 months. Twenty-seven patients (20%) had disease recurrence and 20 (15%) died. Patients in the ABR group were more likely to have nodal involvement (chi-square p = 0.011). Patients treated with ABRs ( n = 26, 20%) compared with ASRs ( n = 106, 80%) had significantly shorter median EFS (32.4 months vs not reached (NR), p < 0.001), DFS (26.2 months vs NR, p < 0.001), and OS (49.2 months vs NR, p < 0.001). The shorter survival observed in the ABR group persisted after adjusting for nodal status and on multivariate analysis. Of the 26 ABR-treated patients, 9 (35%) had an anthracycline added after suboptimal response to an ASR. Regardless of reason for anthracycline inclusion, the survival outcomes were similar. No cardiac or secondary leukemic events were observed in either group. Conclusion: ABRs were associated with shorter EFS, DFS, and OS, even after adjusting for certain high-risk clinical features.

show abstract

“…TNBC is the most aggressive cancer among various breast cancer subtypes. Chemotherapy is the standard treatment for TNBC, but there is a poor overall survival rate and complete pathological response (pCR) 28 . However, in TNBC patients, anthracycline-based therapies showed higher pCR and overall survival.…”

Section: Cell Cycle Assaymentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Among various subtypes of breast cancer, triple-negative breast cancer (TNBC) is aggressive breast cancer. Doxorubicin is the standard therapy used for treating TNBC, but poses a risk of severe adverse effects affecting patient compliance. Hence, there is a need for therapy that reduces the adverse effect and increase compliance for better overall pathological complete response (pCR). Metformin, widely used as an antidiabetic, has gained momentum for its preventive potential and delaying various cancers, including breast cancer, owing to its high safety and better tolerability. Hesperidin, commonly found in citrus fruits, is an integral part of daily diet and consumed worldwide. The objective of the current study was to investigate the potentiation of anti-proliferative effect of doxorubicin using metformin and hesperidinon MDA-MB-468 human breast cancer cell line. The IC50 concentration of doxorubicin (1 µM) was combined with nontoxic doses of metformin (0.5, 1, and 2 mM) and hesperidin (5, 10, and 20 µM). Metformin (1 mM) and hesperidin (5 µM) in combination with doxorubicin (1 µM) inhibited the migration of MDA-MB-468 cells in a scratch assay. In Annexin V-FITC assay, a combination of doxorubicin, metformin, and hesperidin exhibited an increase in cells in late and early apoptosis phase.Further, when cell cycle analysis was performed, cells shifted from G0/G1 phase to S phase, ultimately leading to the arrest of cells in S phase. Hence, the results are conclusive of potentiation of the antiproliferative effect of doxorubicin using metformin and hesperidin on human breast cancer cell line MDA-MB-468. INTRODUCTION:Breast cancer (BC) is the leading cause of cancer, accounting for 2.3 million cases worldwide 1 . Triple-negative breast cancer (TNBC) is the most aggressive cancer among various breast cancer subtypes. TNBC accounts for 10-20 % of cases of BC 2 .

show abstract

Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer

Cited by 4 publications

References 15 publications

Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience

Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

Untitled

Contact Info

Product

Resources

About